- Home
- PASW vs BLRX Comparison
PASW vs BLRX Comparison
Compare PASW & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASW
- BLRX
- Stock Information
- Founded
- PASW 2021
- BLRX 2003
- Country
- PASW Hong Kong
- BLRX Israel
- Employees
- PASW N/A
- BLRX N/A
- Industry
- PASW Apparel
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PASW Consumer Discretionary
- BLRX Health Care
- Exchange
- PASW Nasdaq
- BLRX Nasdaq
- Market Cap
- PASW 15.9M
- BLRX 17.1M
- IPO Year
- PASW N/A
- BLRX 2011
- Fundamental
- Price
- PASW $0.75
- BLRX $3.68
- Analyst Decision
- PASW
- BLRX Strong Buy
- Analyst Count
- PASW 0
- BLRX 2
- Target Price
- PASW N/A
- BLRX $19.00
- AVG Volume (30 Days)
- PASW 394.3K
- BLRX 28.3K
- Earning Date
- PASW 11-15-2025
- BLRX 11-24-2025
- Dividend Yield
- PASW N/A
- BLRX N/A
- EPS Growth
- PASW N/A
- BLRX N/A
- EPS
- PASW N/A
- BLRX N/A
- Revenue
- PASW $8,286,193.00
- BLRX $17,251,000.00
- Revenue This Year
- PASW N/A
- BLRX N/A
- Revenue Next Year
- PASW N/A
- BLRX N/A
- P/E Ratio
- PASW N/A
- BLRX N/A
- Revenue Growth
- PASW N/A
- BLRX 1.19
- 52 Week Low
- PASW $0.69
- BLRX $2.30
- 52 Week High
- PASW $5.40
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- PASW N/A
- BLRX 43.35
- Support Level
- PASW N/A
- BLRX $3.51
- Resistance Level
- PASW N/A
- BLRX $3.89
- Average True Range (ATR)
- PASW 0.00
- BLRX 0.25
- MACD
- PASW 0.00
- BLRX -0.03
- Stochastic Oscillator
- PASW 0.00
- BLRX 17.17
About PASW Ping An Biomedical Co. Ltd. Ordinary Shares
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.